Can you fairly compare a prescription drug and a supplement?
Yes, on the axis that matters: what each one's studies actually measured, in whom, and against what control. The two products sit in different oversight lanes. Enclomiphene is a prescription drug that is not FDA approved; it is compounded per prescription by pharmacies, and a clinician decides who gets it. Tongkat ali is sold as a dietary supplement. FDA does not preapprove dietary supplements for safety or effectiveness before sale, although manufacturers retain safety, labeling, claims-substantiation and manufacturing duties and FDA can act postmarket.7 Neither lane tells you whether the product works. Only the studies can do that.
Most pages on this comparison do not attempt it. Supplement reviews quote tongkat ali's famous numbers without reading the studies behind them, and drug sellers wave the supplement away without engaging its data at all. This page does the unfashionable thing and reads both sides properly, because tongkat ali has some genuine signals, and because its most-quoted numbers are not what they look like.
“The honest comparison is not drug versus plant. It is evidence versus evidence.”
What does tongkat ali actually do to testosterone?
Probably something, in some people, and much less than its famous numbers suggest, because those numbers do not measure what buyers assume they measure. Three studies carry nearly all the weight in tongkat ali marketing, and each reads differently once you check who was studied and what was measured.
Start with the "+37% testosterone" figure quoted everywhere. It comes from a 2013 trial in which 63 moderately stressed adults took 200 mg a day for four weeks, and the increase was in salivary testosterone, measured in stressed adults of both sexes: 31 of the 63 participants were women.1 The study was placebo-controlled, which is more than most supplement research can say. But it did not measure blood testosterone, it did not study men with low levels, and its lead author is affiliated with a supplement-industry company. Whatever it shows, it is not "37% more testosterone" in the sense a low-T advertisement implies.
The second famous number is "90.8% of men reached normal testosterone." It comes from a 2012 report of 76 selected completers from a much larger starting group. After 200 mg a day for one month, mean serum testosterone rose from 5.66 to 8.31 nmol/L, about 46.8%, and the share classified as normal rose from 35.5% to 90.8%.2 The weakness is not missing average data. It is no control group, no randomization or blinding, and strong completer selection, so treatment cannot be separated from selection, time or regression to the mean.
The best evidence is a 2022 meta-analysis that pooled the randomized trials, all five of them. It found a statistically significant rise in total testosterone with wide uncertainty around its size, a standardized mean difference of 1.352 with a confidence interval from 0.565 to 2.138, and its authors wrote that more research is required before use in clinical practice.3 That is the fair summary of tongkat ali: a genuine preliminary signal resting on five small trials. The standardized effect cannot be translated into a single ng/dL gain; studies were heterogeneous, and seven of nine studies in the review used the same commercial extract. It even stands out within its own category. A 2024 systematic review of 52 studies of marketed testosterone boosters found most fail to raise testosterone, and rated tongkat ali among the few "possibly effective" ingredients.4
Newer evidence also includes a null result. A 2026 randomized conference abstract assigned 90 infertile men aged 20 to 45 with baseline testosterone of 350 to 600 ng/dL to tongkat ali, multivitamins or both for 12 weeks; 83 completed the study, and no arm showed a significant change in testosterone or FSH.8 The abstract does not report the tongkat dose, so it cannot settle efficacy, but it belongs beside the positive studies.
“Two questions expose most supplement headlines: who was studied, and what was actually measured.”
What does enclomiphene do by comparison?
Randomized trials show that SERMs raise serum testosterone in men with low levels. A 2025 meta-analysis pooling clomiphene and enclomiphene RCTs found total testosterone 273.76 ng/dL higher than placebo (95% CI 191.87 to 355.66), with high heterogeneity (I2=89%).5 That is a pooled SERM estimate, not an enclomiphene-only effect. It measures a hormone surrogate, not symptom relief, pregnancy or live birth.
The honesty has to run both ways, so here are enclomiphene's limits. No new randomized trial has been published since its phase III program ended: everything more recent is meta-analysis of the old trials, retrospective series, and reviews. FDA and EMA reviewed the development program but did not approve it, concluding that testosterone and semen surrogates did not demonstrate meaningful clinical benefit. EMA also cited venous thromboembolism cases, including one fatal event, while causality and incidence remained uncertain.910 It currently exists as a compounded, prescription-only product under FDA interim enforcement discretion, not an approval.11 It is used for one pattern, secondary hypogonadism, where the testes work but the brain's signal is weak. Men whose testes have failed cannot respond to a signal-boosting drug, and an honest provider declines them.
You will notice there is no chart on this page setting one product's number against the other's. That is deliberate. A percentage change in salivary testosterone in stressed volunteers and a serum change in ng/dL in hypogonadal men are measurements of different things in different people, and a graph putting them on one axis would be exactly the dishonesty this page exists to call out. The table below is the comparison.
Which study numbers can actually be compared?
Not all testosterone numbers share a unit, population or endpoint. This table keeps them on their original scale.
| Source | Population and design | Measured result | What it cannot show |
|---|---|---|---|
| Talbott 2013 | 63 stressed adults, including 31 women; placebo controlled; 4 weeks | Salivary testosterone, 37% relative treatment effect1 | Serum ng/dL change or treatment of male hypogonadism |
| Tambi 2012 | 76 selected male completers; uncontrolled; 1 month | Serum testosterone 5.66 to 8.31 nmol/L2 | A causal effect without a control group |
| Leisegang 2022 | Five small heterogeneous RCTs | Standardized mean difference 1.352 (95% CI 0.565 to 2.138)3 | A single ng/dL effect or interchangeable retail dose |
| 2026 EJE abstract | 90 infertile men; randomized; 12 weeks | No significant testosterone or FSH change; dose not reported8 | A definitive product-wide conclusion from an abstract |
| Hohl 2025 | Pooled clomiphene and enclomiphene RCTs versus placebo | Serum testosterone +273.76 ng/dL; I2=89%5 | An enclomiphene-only effect or patient-important benefit |
Enclomiphene vs tongkat ali at a glance
The comparison, measure by measure, without treating unlike studies or finished products as interchangeable.
| Measure | Enclomiphene | Tongkat ali |
|---|---|---|
| What it is | Oral prescription drug, a purified isomer of clomiphene, that signals the body to raise its own testosterone | Root extract of the Southeast Asian shrub Eurycoma longifolia, sold as a dietary supplement |
| Oversight lane | Not FDA approved; compounded per prescription by pharmacies | Dietary supplement; no FDA preapproval for safety or effectiveness, with manufacturer duties and postmarket oversight7 |
| Best evidence | Placebo-controlled pooled clomiphene and enclomiphene serum RCTs; hormone surrogate, not proven clinical benefit5 | Preliminary 5 small pooled RCTs, uncontrolled series and a 2026 null randomized abstract38 |
| Whom studied | Mixed clomiphene and enclomiphene trial populations with low serum testosterone5 | Mixed: moderately stressed adults of both sexes, small groups of men with low testosterone123 |
| Effect on LH and FSH | Raises both5 | Not established |
| Cash-cost comparison | Varies by product, dose, seller, testing, clinical services and location; price does not establish product equivalence. | |
| Requires a prescription | Yes | No |
| Fertility data | LH, FSH and semen surrogates studied; pregnancy and live-birth benefit not established5 | Not established; the pooled trials measured testosterone, not fertility3 |
Does supplement quality matter?
Yes, and for tongkat ali it matters more than most, because the trial evidence belongs to specific standardized extracts, not to the category. Published studies used heterogeneous preparations and about 100 to 600 mg a day, over periods from days to months. Several influential trials used one standardized commercial water extract.312 A retail bottle may contain a different extraction, a different concentration, or a different dose, and no one reviews any of that before it goes on sale.
Quality is not hypothetical either. A 2006 survey of 100 Malaysian products marketed as tongkat Ali hitam found 26 above Malaysia's 0.5 ppm mercury limit, with measured values from 0.53 to 2.35 ppm.13 That survey does not estimate contamination in the current US market. It shows why geography, date, identity and batch testing matter, and why matching milligrams does not validate a retail product.
When does a supplement make sense?
When there is nothing confirmed to treat. A man with borderline symptoms and no confirmed deficiency loses little by starting with the levers that carry the strongest non-prescription evidence, and those are not capsules: sleep, weight and alcohol, covered in our guide to raising testosterone naturally. Potential benefit from tongkat ali remains uncertain and extract-specific. EFSA evaluated one standardized water extract proposed at 200 mg a day and concluded that safety could not be established because of genotoxicity concerns.14 That does not prove that usual human doses cause harm, but it means the choice should not be framed as risk-free or low stakes.
Do not use one self-ordered testosterone value as a pass-or-fail supplement test. Testosterone varies, and no validated laboratory response threshold exists for tongkat ali. Persistent symptoms call for diagnosis with repeat testing and clinical context, not serial self-experimentation.
When is it time for the prescription conversation?
When low testosterone stops being a suspicion and becomes a diagnosis. The standard is specific: compatible symptoms or signs plus unequivocally and consistently low testosterone measured with a reliable assay, confirmed by a repeat morning fasting total-testosterone test.6 The cause then needs evaluation. At that point you are no longer weighing a drug against a plant; you are choosing a treatment for a diagnosed condition, and no supplement has trial evidence adequate to treat one: the authors of tongkat ali's own meta-analysis say more research is required before clinical use.3
From there the realistic conversation is between actual therapies. Who qualifies for enclomiphene explains the LH and FSH pattern that predicts response, and why an honest provider declines a share of the men who apply. The wider choice, between raising your own production and replacing it from outside, is the subject of our enclomiphene vs TRT comparison. Whichever way that conversation goes, it starts with proper measurement, not with a bottle.
Common questions
Does tongkat ali raise testosterone in healthy men?
Evidence in healthy or non-hypogonadal men is mixed and short term.
A 32-man, two-week study using 600 mg reported hormone changes, while a 2026 randomized abstract in 90 infertile men with baseline testosterone of 350 to 600 ng/dL found no significant testosterone or FSH change over 12 weeks. Neither establishes treatment benefit for diagnosed hypogonadism.
Can you take tongkat ali and enclomiphene together?
Nobody knows, because no interaction data exists: no study has tested the combination, so no one can tell you it is useful, harmful, or neither.
If you are prescribed enclomiphene, tell the prescriber everything you take, including supplements. That is not bureaucracy; it is how problems get caught before they happen.
What dose of tongkat ali was used in the studies?
Published studies used heterogeneous preparations and about 100 to 600 mg a day over periods from days to months.
Several influential trials used one standardized commercial water extract. Matching milligrams alone does not make a retail product equivalent, and this evidence does not establish a recommended dose.
Are testosterone boosters FDA approved?
Dietary supplements are not preapproved by FDA for safety or effectiveness before sale.
Manufacturers remain responsible for lawful labeling, safety, claims substantiation and manufacturing requirements, and FDA can act after products reach the market. That oversight does not make label confidence evidence of effectiveness.
References
- 1.Talbott SM, Talbott JA, George A, Pugh M. Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects. Journal of the International Society of Sports Nutrition. 2013;10(1):28.
- 2.Tambi MI, Imran MK, Henkel RR. Standardised water-soluble extract of Eurycoma longifolia, Tongkat ali, as testosterone booster for managing men with late-onset hypogonadism? Andrologia. 2012;44 Suppl 1:226-230.
- 3.Leisegang K, Finelli R, Sikka SC, Panner Selvam MK. Eurycoma longifolia (Jack) improves serum total testosterone in men: a systematic review and meta-analysis of clinical trials. Medicina (Kaunas). 2022;58(8):1047.
- 4.Morgado A, Tsampoukas G, Sokolakis I, et al. Do “testosterone boosters” really increase serum total testosterone? A systematic review. International Journal of Impotence Research. 2024;36(4):348-364. doi:10.1038/s41443-023-00763-9.
- 5.Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025;69(5):e250093.
- 6.Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2018;103(5):1715-1744.
- 7.US Food and Drug Administration. Questions and answers on dietary supplements. FDA consumer guidance. Current page accessed 21 August 2026.
- 8.Suyono SS, Tjandrawinata RR. Longitudinal effects of Eurycoma longifolia extract and multivitamin supplementation on reproductive hormone profiles in infertile men: a randomized controlled trial. European Journal of Endocrinology. 2026;195(Supplement 1):lvag096.1600. doi:10.1093/ejendo/lvag096.1600.
- 9.US Food and Drug Administration. Pharmacy Compounding Advisory Committee briefing document: enclomiphene citrate. Meeting of 8 June 2022.
- 10.European Commission. Commission implementing decision refusing marketing authorisation for EnCyzix (enclomifene). 6 April 2018.
- 11.US Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A: categories list. Updated 14 May 2026.
- 12.Chan KQ, Stewart C, Chester N, Hamzah SH, Yusof A. The effect of Eurycoma longifolia on the regulation of reproductive hormones in young males. Andrologia. 2021:e14001. doi:10.1111/and.14001. PMID:33559971.
- 13.Ang HH, Lee KL. Contamination of mercury in tongkat Ali hitam herbal preparations. Food and Chemical Toxicology. 2006;44(8):1245-1250. PMID:16567029.
- 14.EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of a standardised aqueous extract from the roots of Eurycoma longifolia Jack as a novel food. EFSA Journal. 2021;19(12):6937.
This article is for general education and is not medical advice, a diagnosis, or a treatment recommendation. It does not create a clinician and patient relationship. Talk to a licensed clinician about your own situation, and call your doctor or 911 for anything urgent.